adafosbuvir: Clinical Trials

12 trials of adafosbuvir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

10 completed, 1 terminated, 1 withdrawn. 9 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 19Completed 7, Terminated 1, Withdrawn 1
Phase 23Completed 3

Follow adafosbuvir: new trials by email Literature Review of adafosbuvir trials Research Report on adafosbuvir

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Odalasvir and AL-335 Alone and in Combination With Simeprevir in Participants With Moderately Impaired Hepatic Function
AL-335 800 mg, ODV 25 mg, SMV 75 mg - Hepatic Impairment
Phase 1WithdrawnJanssen Research & Development, LLC2017-09-112017-10-11
A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants
ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV) - Healthy
Phase 1CompletedJanssen Research & Development, LLC592017-05-122017-11-14
Study to Assess the Relative Bioavailability of Fixed-Dose Combination (FDC) Tablet (Simeprevir, Odalasvir and AL-335) Compared With Single Agents Administered Together, and to Assess the Effect of Multiple-Dose Lansoprazole or Omeprazole on Single-Dose Pharmacokinetics of SMV, ODV, and AL-335 (FDC)
Simeprevir 75 mg, Odalasvir 25 mg, Odalasvir 12.5 mg - Healthy
Phase 1TerminatedJanssen Research & Development, LLC722017-02-202017-12-22
A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive
AL-335, Odalasvir (ODV), Simeprevir (SMV) - Hepatitis C, Chronic
Phase 2CompletedJanssen Pharmaceutical K.K.332016-12-212019-09-11
Efficacy and Safety of Combinations of AL-335, Odalasvir (ODV) and Simeprevir (SMV) in the Treatment of Chronic Hepatitis C Infection
AL-335, Odalasvir, Simeprevir - Hepatitis C, Chronic
Phase 2CompletedJanssen Research & Development, LLC3652016-11-092019-11-20
A Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of AL-335
AL-335 - Renal Insufficiency
Phase 1CompletedJanssen Research & Development, LLC242016-09-132017-12-20
To Evaluate the Effects of Odalasvir and AL-335 With Simeprevir on the Single-Dose Pharmacokinetics of Ethinylestradiol and Drospirenone in Healthy Female Participants
Drospirenone/ethinylestradiol, AL-335, Odalasvir (ODV) - Healthy
Phase 1CompletedJanssen Research & Development, LLC242016-08-012017-01-23
Study to Investigate the Pharmacokinetics, Safety and Tolerability of Odalasvir and AL-335 in Healthy Japanese Participants
Odalasvir (ODV), AL-335, Placebo - Healthy
Phase 1CompletedJanssen Research & Development, LLC402016-06-142018-03-29
Study to Investigate the Pharmacokinetic Interaction Between 2 Direct Acting Antiviral Agents Odalasvir and AL-335 and Between 3 Direct Acting Antiviral Agents Simeprevir, Odalasvir and AL-335 at Steady State in Healthy Japanese Participants
AL-335, Odalasvir (ODV), Simeprevir (SMV) - Healthy
Phase 1CompletedJanssen Research & Development, LLC222016-05-012025-02-03
A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of the Combination of AL-335, Odalasvir, and Simeprevir
AL-335, Odalasvir (ODV), Simeprevir (SMV) - Chronic Hepatitis C
Phase 2CompletedAlios Biopharma Inc.1612015-10-312019-07-16
A Study to Evaluate the Effect of ACH-3102 and Simeprevir on AL-335 Pharmacokinetics in Healthy Volunteers
AL-335, ACH-3102, Simeprevir - Chronic Hepatitis C
Phase 1CompletedAlios Biopharma Inc.322015-07-312019-10-16
First in Human Study of AL-335; Single Dose, Food Effect in Healthy Volunteers; Multiple Doses in Chronic Hepatitis C Genotype 1
AL-335 matching placebo, AL-335 - Chronic Hepatitis C
Phase 1CompletedAlios Biopharma Inc.1122014-12-312019-10-16

Conditions studied

Hepatitis C, Chronic (5)  ·  Renal Insufficiency (1)

Sponsors

Janssen Research & Development, LLC (8)  ·  Alios Biopharma Inc. (3)  ·  Janssen Pharmaceutical K.K. (1)

Countries

United States (4)  ·  United Kingdom (3)  ·  France (2)  ·  Moldova (2)  ·  Belgium (1)  ·  Canada (1)  ·  Georgia (1)  ·  Germany (1)  ·  Japan (1)  ·  Mauritius (1)  ·  New Zealand (1)  ·  Poland (1)  ·  Singapore (1)  ·  Spain (1)

Results publications

PMID 29736243, PMID 30325939, PMID 30350297

NIH funding

2015 (2), 2016 (1)